Humana Inc: Form 10-Q for the period ended Sep 30, 2022
Filed with the SEC on Nov 2, 2022 and accepted by EDGAR at Nov 2, 2022, 19:07 ET.
Sections
The sections of this filing are being extracted from EDGAR and appear here in about a minute. Meanwhile, read the original on sec.gov. The main document on sec.gov.
Figures reported in this filing
Standardized line items from the XBRL in this filing, for the period ended 2022-09-30. Comparative periods it repeats are left out.
| Line item | Period | Value | XBRL concept |
|---|---|---|---|
| Revenue | 3 months2022-07-01 to 2022-09-30 | $22.80bn | us-gaap:Revenues |
| Revenue | 9 months2022-01-01 to 2022-09-30 | $70.43bn | us-gaap:Revenues |
| Selling, general and administrative | 3 months2022-07-01 to 2022-09-30 | $3.06bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Selling, general and administrative | 9 months2022-01-01 to 2022-09-30 | $9.12bn | us-gaap:SellingGeneralAndAdministrativeExpense |
| Operating income | 3 months2022-07-01 to 2022-09-30 | $1.17bn | us-gaap:OperatingIncomeLoss |
| Operating income | 9 months2022-01-01 to 2022-09-30 | $3.68bn | us-gaap:OperatingIncomeLoss |
| Interest expense | 3 months2022-07-01 to 2022-09-30 | $102.0m | us-gaap:InterestExpense |
| Interest expense | 9 months2022-01-01 to 2022-09-30 | $293.0m | us-gaap:InterestExpense |
| Income tax | 3 months2022-07-01 to 2022-09-30 | $107.0m | us-gaap:IncomeTaxExpenseBenefit |
| Income tax | 9 months2022-01-01 to 2022-09-30 | $820.0m | us-gaap:IncomeTaxExpenseBenefit |
| Net income | 3 months2022-07-01 to 2022-09-30 | $1.20bn | us-gaap:NetIncomeLoss |
| Net income | 9 months2022-01-01 to 2022-09-30 | $2.82bn | us-gaap:NetIncomeLoss |
| Diluted EPS | 3 months2022-07-01 to 2022-09-30 | $9.39 | us-gaap:EarningsPerShareDiluted |
| Diluted EPS | 9 months2022-01-01 to 2022-09-30 | $22.16 | us-gaap:EarningsPerShareDiluted |
| Basic EPS | 3 months2022-07-01 to 2022-09-30 | $9.45 | us-gaap:EarningsPerShareBasic |
| Basic EPS | 9 months2022-01-01 to 2022-09-30 | $22.27 | us-gaap:EarningsPerShareBasic |
| Diluted shares (weighted) | 3 months2022-07-01 to 2022-09-30 | 127,356,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Diluted shares (weighted) | 9 months2022-01-01 to 2022-09-30 | 127,305,000 shares | us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding |
| Operating cash flow | 9 months2022-01-01 to 2022-09-30 | $9.71bn | us-gaap:NetCashProvidedByUsedInOperatingActivities |
| Capital expenditure | 9 months2022-01-01 to 2022-09-30 | $862.0m | us-gaap:PaymentsToAcquirePropertyPlantAndEquipment |
| Dividends paid | 9 months2022-01-01 to 2022-09-30 | $291.0m | us-gaap:PaymentsOfDividends |
| Share repurchases | 9 months2022-01-01 to 2022-09-30 | $1.03bn | us-gaap:PaymentsForRepurchaseOfCommonStock |
| Cash and equivalents | At period end2022-09-30 | $13.56bn | us-gaap:CashAndCashEquivalentsAtCarryingValue |
| Current assets | At period end2022-09-30 | $33.71bn | us-gaap:AssetsCurrent |
| Total assets | At period end2022-09-30 | $50.77bn | us-gaap:Assets |
| Current liabilities | At period end2022-09-30 | $25.05bn | us-gaap:LiabilitiesCurrent |
| Total liabilities | At period end2022-09-30 | $34.45bn | us-gaap:Liabilities |
| Long-term debt | At period end2022-09-30 | $7.80bn | us-gaap:LongTermDebtNoncurrent |
| Current portion of debt | At period end2022-09-30 | $2.80bn | us-gaap:DebtCurrent |
| Shareholders' equity | At period end2022-09-30 | $16.32bn | us-gaap:StockholdersEquityIncludingPortionAttributableToNoncontrollingInterest |
| Shares outstanding | At period end2022-09-30 | 126,600,318 shares | dei:EntityCommonStockSharesOutstanding |
Source: SEC EDGAR, the filing index for accession 0000049071-22-000071. Last ingested by Listed: Oct 24, 2026, 14:53 ET. Listed shows no prices and gives no investment advice.